Become a Member

“Living Metal… Tiny Company has Monopoly… $141,478 for a Thimbleful”

Checking out Michael Robinson's teaser for the "The Medical Discovery of the Century"

By Travis Johnson, Stock Gumshoe, August 12, 2014

Ok, this is definitely the “most requested” ad over the last 24 hours — I can’t tell you how many folks have asked your friendly neighborhood Gumshoe to look into “Living Metal,” but the list is getting loooong.

And we are, of course, happy to oblige.

The pitch is from Michael Robinson for his Radical Technology Profits, and it’s not just about a hot new biotech company that has a cure for cancer and Alzheimer’s and all kinds of other diseases… it’s about a hot new biotech company that you can buy before it goes public through their Money Morning Prospectus! How exciting is that!?

Well, of course the answer is “super exciting, but usually stupid” … venture investors in biotech companies lose most of the time, just like most venture tech investors lose on most investments. They make it up with the few companies that do spectacularly well out of a hundred or more, of course, but developing a drug even to the point of approval for Phase 1 clinical trials can be incredibly expensive and time consuming — and Phase 1 is often five years or more before a company actually generates any revenue. The allure is always there because we imagine the vast riches from the folks who “get in early,” but unless you’re an expert and you’re “getting in early” on dozens of quality opportunities the odds are stacked pretty heavily against you.

So that’s the initial warning — and I have no idea yet whether Robinson is actually trying to do a private placement of shares, which would be a big and dangerous leap for a newsletter editor to take, or if he’s just trying to give you the impression that he’s going to get you “private” shares. We’ll see as we dig into the teaser.

Here’s how Robinson gets the juices flowing:

“A thimble full of this…

“Living Metal

“Sells for $141,748

“One tiny company has a monopoly on it
“It’s sales are set to surge 24,474% over the next 15 months
“And it could go public on the NASDAQ as soon as August 31”

And he uses the thimble imagery to help us understand just how valuable this stuff is … he says a thimble of gold would be $1,319, a thimble of platinum $1,437, a thimble of diamonds $11,581. And then…

“But it’s just a drop in the bucket compared to what I’m going to show you today.

“Containing both biological and metallic properties, it’s classified as a Living Metal.

“And it can only be found in one small stretch of underwater territory, 14 miles off the coast of the Channel Islands.

“However, its scarcity is not why a thimble full of this Living Metal is currently selling for $141,748.”

So… the image of the bluish liquid and the Channel Islands reference is enough to tell us which company they’re teasing (and yes, it’s a public company — it’s just not on a major exchange), but we’ll let the suspense build for a few minutes…

More clues…

“An international panel of 15 doctors from the University of Liverpool, London’s Institute of Neurology, and the Alzheimer’s Institute in the U.S. have collectively analyzed this Living Metal.

“They officially concluded that it can ‘prevent and possibly treat Alzheimer’s dementia.'”

Wowsers!

“124 advanced clinical trials are progressing rapidly.

“They’re taking place at Penn, Baylor, Loyola University, UCLA, and the most cutting-edge medical facilities.

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“And they’re all coming to the same conclusion.

“This Living Metal can literally reprogram the human immune system to such a degree…

“It can make us totally immune – totally impervious – to some of the most dangerous diseases known to man.”

OHMYGOD are you peeing your pants with excitement yet?

“… it should come as no surprise, that even though sales of this Living Metal are only $2.63 million…

“The story moving forward is completely different.

“Today, every major pharmaceutical company is fighting to acquire as much as they possibly can.

“I’m talking about: Bayer, Pfizer, GlaxoSmithKline and a Half Dozen Others…

“Right Now They’re Paying $141,748 For Just a Thimble Full of This Living Metal….

“That’s because the FDA is set to green-light a series of Living Metal treatments that could solve the greatest medical challenges of our generation.

“And estimates suggest sales of this breakthrough are about to aggressively rise as much as 23,474% in the next 15 months.

“As I’m going to show you today…

“This Living Metal is Looking at Potential Sales of $620 Million Per Year.

“And One Company Has a Monopoly on it.”

Exciting, right? Sales going from $2.63 million to $620 million would be crazy growth that investors would absolutely salivate over. So who’s the company?

“Never in My Career Have I Come Across a Venture Like the One I’m About to Share With You

“Before I begin, let me tell you that there is a catch.

“The company who holds a monopoly on this Living Metal is not listed on the New York Stock Exchange or NASDAQ.

“You won’t find it on the OTC Pink Sheets.

“And you won’t find it on the London, Tokyo, or any of the major foreign exchanges.

“In fact, of the 27.8 million U.S. companies… both public and private…

“There are only 87 with the unique classification this biotech firm holds….

“I’ll reveal how you can become what’s called a ’round lot’ investor BEFORE it ‘goes public’ on the NASDAQ.
Which the CEO himself believes could happen as soon as August 31st.”

OK, so yes, the company is not listed on the NYSE or the Nasdaq or other major foreign exchanges, and it’s not technically on the pink sheets… but it is listed on the Venture exchange in Canada (used to be called the Vancouver exchange, it’s mostly junior mining stocks) and it does trade on the OTCQB, which is a little subset of the over the counter listings that are not quite as big and transparent as the OTCQX but do pass more “listing” requirements than the OTC Pink Sheets.

The stock is, as several readers have guessed already, Stellar Biotechnologies (KLH.V in Canada, SBOTF on the OTCQB)

And yes, if you so desire you can easily go buy “round lots” either in Canada or through most any US broker on the OTCQB — you can probably buy odd lots through most brokers, too, though hopefully anyone considering a $2,000 newsletter is willing to buy at least 100 shares of a $1 stock (“round lots” just means you’re buying in 100-share increments for most stocks, though sometimes it could be 1,000 or more for lower-priced shares). You don’t need a “Money Morning Prospectus” to buy Stellar shares, though I’m sure they provide a lot more research on the stock than I’ve done.

If you’d like to hear the “bull” case on Stellar, it’s probably best to get it right form the horse’s mouth — they are very promotional in getting their story out, CEO Frank Oakes presented at the Stansberry conference for investors in June and you can see the video of that presentation here, or the slightly more updated powerpoint slides here. Those include lots of pages of customers and potential customers for their Stellar KLH, including many drugs in clinical trials that use the stuff.

What does it do? Well, here’s Robinson’s description:

“Your Immune System Can’t Tell Which Cells Are Keeping You Alive and Which Could Be Giving You Alzheimer’s…

“And That’s Where This Living Metal Comes Into Play.

“Its scientific name is Megathura Crenulata hemocynanin.

“We’ll call it MCh for short.

“MCh is a very rare type of protein that has both biological and metallic properties.

“In other words, it’s part membrane – just like your blood cells – and part metal.

“And that combination gives it a unique ability.

“This Living Metal, MCh, Can Actually Reprogram the Immune System of Those Suffering From Alzheimer’s.”

Well, Robinson can call it MCh if he wants to — everyone else calls Megathura Crenulata by its common name, the Keyhole Limpet, and they refer to the pharmaceutical ingredient as Keyhole Limpet Hemocyanin, or KHL. Which is what Stellar’s ticker symbol is in Canada, cleverly enough, so we can see why the teasermeisters made up a new name to obscure it.

This is what’s described as an immunogen — a molecule that can’t be destroyed by your immune system, but which can carry haptens into your system to provoke a strong and sustained immune response, fighting off whatever it is you’re trying to fight (cancer cells, amyloid, etc.). That’s not a technical description and it may not be entirely accurate, but KLH’s anticipated value is in immunotherapy.

And the “unique selling proposition” for Stellar Biotechnologies is that they are the only ones who can scale up mass production of KLH from the Keyhole Limpets — because these limpets are (or are becoming) endangered and are in very limited supply in the wild. Pharmaceutical companies can’t rely on divers finding more limpets to use in extracting the protein from them, so the government and other investors funded Oakes as he developed an aquaculture system to create a domesticated and reproducing population of limpets on land. They also developed a method for extracting the hemocyanin from the limpets’ blood without killing them, so they can continue to reuse the limpets and extract more each year as new generations are born and reach maturity.

With the idea, presumably, that they can keep scaling this up over and over — they’ll just need to add more tanks to their aquaculture facility, add more labs to extract and purify the stuff, and track the manufacturing. They say they are the only source of GMP (good manufacturing practices) KHL, and they have at least a five-year lead over anyone else who might want to build a similar aquaculture facility.

So … how will that make us rich? Well, from what I can tell it’s going to have to be from dramatically higher pricing for KLH if and when it becomes a part of a commercial product — right now it’s sold for research purposes, both in researching KLH-based immunotherapies and as a way to test the immune response of other compounds, and Sigma Aldrich has public pricing (presumably they’re selling Stellar KLH, though it’s not branded) at $287 for 100mg. That doesn’t mean this is the price a pharmaceutical company would pay if they came to KLH and said they needed a commercial-scale quantity for a new drug in a year or two, but it’s the only baseline I have to go from. 100 mg is a tenth of a gram.

A thimble probably holds two or three milliliters, and the KLH product is in a vial of 0.75ml of solution for 20 milligrams, so we’ll be charitable and say that we can fit five of these vials in a thimble… maybe you have big fingers. That would be roughly 100 milligrams of KLH, so that gives us $287 as the retail price for a tenth of a gram which is something close to what would fit in a thimble… unless I’m missing a decimal point somewhere (no, it’s not exact — but it doesn’t have to be). If I am missing something substantial, please tell me, I’m certainly out of my element on this one.

So right now, despite the fact that the company’s presentation says that one gram of KLH has commercial value of $40-50,000 and Michael Robinson says a thimbleful (a tenth of a gram) is going for $141,000, it’s apparently selling for $2,870/gram ($287 for a five pack of 20-milligram vials, times ten equals one gram).

Back in 2011, when the company was expanding their aquaculture facility, they estimated annual demand at 2,000 grams a year and said that their expansion would get them to 20,000 grams a year. That would mean, if they sold the KLH at that $2,870/gram price (not $40,000), their revenue potential would be about $57 million.

Now, in this last quarterly filing, they say that “Given sufficient funding to continue scale-up, Stellar’s projected production capacity is 4-5 kilograms per year within the next four years, and
up to 20 kilograms per year a few years after that, depending on customers’ requirements and our ability to execute supply commitments.” A kilogram is 1,000 grams, so it sounds like they’re still well below 4,000 grams of production and/or demand today.

Current revenue, including everything (contract revenue and distributor sales) at the run rate of the last quarter, is $400,000 a year. If we assume that they’re getting half of the price that their distributor charges, that $400,000 in revenue per year would mean that they’re only selling about 300 grams a year. That seems unlikely, so perhaps they’re selling it for less… or more of their contract revenue is not specifically associated with the sale of KLH. if we assume they can get that $40,000 a gram that their presentation says is the commercial value, and they can produce 5,000 grams within the next four years (and there is commercial demand), then that gives us the possibility that they could generate $160 million in revenue in four years.

That would be tremendous for a company of this size (Stellar’s market cap is about $100 million now), and should generate a huge profit if such a scenario is really feasible (they’re burning through about $15 million a year in cash at the current rate)… but that’s about where I usually lose interest in the Stellar story — assuming everything else works out, I just don’t get how the stuff gets to $40,000 a gram. Doesn’t mean it’s impossible, of course, I just don’t get it — and there’s plenty of stuff to invest in that I understand a lot better.

They do have a partnership deal with Amaran, a Taiwanese biotech firm that invested $5 million in the company last year and is investigating KLH use in immunotherapy for a couple different kinds of cancer and is apparently in phase II/III clinical trials with those. And they do also have their own clostridium difficile vaccine that they’re trying to develop — that’s still preclinical, though they say their goal for the second half of this year is to advance toward an IND filing (that would mean they’re getting ready to file with the FDA for permission to test in humans, getting to the point where they could do a Phase 1 trial).

But really, those are speculative bets on drugs that I know nothing about — and their own C. difficile vaccine is so very early in the process that it’s impossible to assign any value to it. The real pitch for Stellar Biotechnologies is that they are the sole source for a key ingredient, and the mass demand will drive up production and prices in a pretty dramatic fashion as pharmaceutical companies fight to get the quantity they need. So my understanding falls apart at that point because I have absolutely no idea how many molecules of KLH would be required for each dose of a commercial immunotherapy, and what that would mean for how many grams of KLH must be produced from these mollusks, and, in turn, how many mollusks they’d have to have in their aquaculture facility to turn a profit. So without any notion of whether these numbers that they bat around of $40,000 a gram hold any water, I can’t guess at how much money they might eventually be able to make. I’m not willing to bet the farm on their C. difficile preclinical immunotherapy, so until I can understand those future financial metrics somehow Stellar doesn’t appeal to me.

That doesn’t mean it won’t work for you though, of course — you might wish to take a flier, it’s certainly a stock that has been actively promoted and teased many times and they are very promotional themselves with a strong presence at investment conferences, so the fact that I can’t figure out a reasonable future valuation doesn’t mean the stock won’t go up. The story still sounds exciting, the clinical trials creating the demand and driving up the prices just as Stellar is able to ramp up production, but there are so many moving parts and the clarity on actual possible pricing is so lacking that I’ll leave this for others.

Robinson has some pretty strong-sounding “guarantees” for you as well, should you choose to subscribe:

“Guarantee #1: 30-Day Grace Period

“If, for any reason, I feel Radical Technology Profits is not right for me in the next 30 days, I’m entitled to a full refund of my membership. No questions asked.

“Guarantee #2: The NASDAQ Listing Will Take Place By November 30th

“If this company is not listed on the NASDAQ by November 30, 2014, I will receive 12 months of access to Radical Technology Profits service for free.

“Guarantee #3: At Least One Commercialized Drug Will Reach The Market Within 12 Months

“If this biotech firm does not have at least one MCh-based drug reach commercialization before September 2015, I will receive an additional 12 months of access to Radical Technology Profits service for free.”

So… you’ll notice that those second and third quarantees are just that you can get another free year of Radical Technology Profits if he’s wrong — not that you get your $2,000 back. I have seen no preliminary filing for Stellar to get a Nasdaq listing at this point, but it’s certainly possible that they could do so and I have not read all of their filings. Listing on Nasdaq would add another corporate expense, but it would also certainly lift the profile since they’d be hobnobbing with most of the other junior biotech stocks and would get the attention of more US investors — I’d guess that would tend to give the stock a lift, but you can never really tell… it’s still very much a “story” stock without real revenue and a bet on an uncertain future so you can’t make a firm valuation argument about the shares with a straight face whether we’re talking Canadian or US Dollars.

I have no idea from this spiel whether Robinson is really trying to get you to buy into a private placement of shares for Stellar, which is the impression given in the tease about a “prospectus”, but I suppose it’s possible — they’ve had private placements in the past year at close to a dollar a share and they may well do so again. It’s unlikely, really, since the easy way to buy “round lots” is just to place an order for shares on either the venture exchange or, through pretty much any US broker, at the OTCQB exchange that trades just like the pink sheets stocks we so often see.

I know we’ve had many folks here following Stellar Biotechnologies over the past year or so, particularly because it was very, very, very actively teased by the Angel Publishing folks and Jim Skelton started a few discussions about Stellar back when he was “just” an Irregular (before he signed up to be a columnist with us), so hopefully the Stellar-followers out there can chime in and share their thoughts on the company now.

Irregulars Quick Take

Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)
guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

131 Comments
Inline Feedbacks
View all comments
Danny Campbell
August 12, 2014 1:32 pm

Way to go, I asked you about this yesterday. Good report. Much appreciated.

jim lark
jim lark
August 13, 2014 3:00 pm
Reply to  Danny Campbell

i’ve received two separate email alerts
today (aug 13th) from dr. kent moors on
stellar (“liquid metal, etc.”)they’re
really working this one, aren’t they?

Add a Topic
1567
jim lark
jim lark
August 13, 2014 3:17 pm
Reply to  jim lark

just received an email tout from shah’s insights and indictments (aug 13th 3PM), and
yet another “bandwogoneer” pumping SBOTF. living metal, “LIVES!”

Jim Leavenworth
Jim Leavenworth
August 25, 2014 8:33 pm
Reply to  jim lark

Now if it can just protect us against those government stockpiled hollow point bullets the Shah is trying to scare us about SBOTF will really skyrocket. But don’t believe me ask Cliven Bundy, Ha, Ha!

M Stack
M Stack
August 26, 2014 11:36 am

government stockpiled hollow point bullets are for real, millions of rounds of them with different government agencies.

terrycupp
terrycupp
August 14, 2014 9:54 pm
Reply to  Danny Campbell

google Ebola Filoviridae Virus and KLH and you will dozens of links.

Add a Topic
4282
rlangsford
rlangsford
August 12, 2014 1:56 pm

Robinson also indicates in his teaser that he’ll send out a special form which, when sent to the IRS, will cause them to write us a check due to this company’s special status. Any idea what that’s all about?

👍 6
AllanTrends
August 12, 2014 2:17 pm

I’d be interested in learning the date(s) this teaser started going out. There was a suspicious mid-July spike in volume, as much as 5X average daily volume. During this volume spike the stock popped from $0.60 to a high of $1.16 in about 5 trading days. Volume then subsided for about a week, as price fell back into the 80-90c range until yesterday (Aug 11th) where both price and volume spiked as the stock ran up to $1.25. There was absolutely NO NEWS during this entire three week period that would account for the volume-price spikes….except for the teaser going out. Someone doubled their money from three weeks ago….just lucky….maybe they were aware that a massive email campaign was about to begin?
Link to chart: http://www.allantrends.com/sbotf-2/

Add a Topic
5971
Add a Topic
5971
👍 74
👍 21717
modernrock
Irregular
August 13, 2014 4:48 pm
Reply to  AllanTrends

This tease started near market open on Monday.

👍 255
jfree
Member
jfree
August 12, 2014 2:23 pm

Thanks for the info.!
Even though highly speculative stock I bought a few hundred shares just for kicks! Believe it has limited downside and resistance at the 50 day MA at around 91 cents.
That being said, due to its small cap and price the stock is at its very susceptible to manipulation!

Add a Topic
5971
Add a Topic
5971
Martin
Guest
Martin
August 13, 2014 2:13 pm
Reply to  jfree

I’m very curious, how did you buy the shares? Did you buy “round lots” of private placements somehow or you bought shares on OTCQB?

Add a Topic
5454
modernrock
Irregular
August 13, 2014 4:24 pm
Reply to  Martin

it isn’t a private placement, re read it

👍 255
Jim Leavenworth
Jim Leavenworth
August 25, 2014 8:28 pm
Reply to  modernrock

What Micael Robinson is touting in a video, which in turn was in an email from Shah’s insights and indictments, is a private placement for $1 a share which I suppose will appeal to kids at heart dreaming of being a financial angel. SBOTF can be easily purchased and its closing price today was I believe $1.93. I think this stock has room to run, a lot of room and if you can’t buy a meaningful # of shares at these prices you don’t belong in the market.

Add a Topic
5971
MPatin
MPatin
August 12, 2014 2:25 pm

Read about their technology on their website CAREFULLY. KLH is not itself a cure for any of those indications (Alzheimers, cancer, etc. etc.). It is a vaccine carrier and/or immunological enhancer, not a standalone “drug.” The companies that want this stuff want to incorporate it into their products. Therefore the success of Stellar Bio is tied to the success of these other companies’ upcoming products, and as we know, it is these upcoming products that have to traverse the rigorous FDA approval process. One the one hand, this adds another layer of risk to Stellar’s future, but on the other hand, it might be a good “pick-and-shovel” type play in the biotech area. Just sayin’. As I like to remember, the cure for cancer has always been just around the corner…for the last 40 years.

Add a Topic
3397
Add a Topic
3022
Add a Topic
3397
Paul Jessup
Member
Paul Jessup
August 12, 2014 2:31 pm

Perhaps the limpets get the other $37,000 per gram.

Alan Harris
Guest
Alan Harris
August 16, 2014 4:17 pm
Reply to  Paul Jessup

I believe Limpets have suckers.

LH
Member
LH
August 12, 2014 2:41 pm

There have been Stellar teasers in several places this week, but I didn’t see any earlier in the summer.
It’s a highly interesting company from the science side….
My question was more about something else in the Robinson teaser. He said that in the “package” he would send to subscribers about this company, there was a “form” that
they could file with the IRS to get money back (his example amounted to the initial investment and half the capital gains) after this was listed, and he hinted at some special tax status…Does anyone know if there is some sort of tax break for supporting the listing of certain companies? Some magic form to file with taxes that negates capital gains? Since I imagine almost everyone who read the article knew he was talking about Stellar, I think this “form to send to the IRS” was the real tease. Also, why the facility in under the protection of Marines….

Add a Topic
5916
👍 21717
thi is frank,
August 13, 2014 7:45 pm

the shares that you guys want to buy are in the tsx-v with symbol klh-v, yesterday they where up to $1.46 I haven’t cecked them today, I live in the greater Toronto area an d I am interested sounds to good to pass.

lee kraus
lee kraus
August 18, 2014 1:47 pm

Most immunogens for vaccination are in the microgram (0.000001g) range. The immunogen that is produced by modifying the KLH for use as a vaccine might be very expensive.

Add a Topic
6113
tnfleener
tnfleener
August 12, 2014 3:34 pm

I read that the were going to be listed on the NASDAQ, if this is true that could bump it up as well.

👍 -2
Glenn Garland
Guest
Glenn Garland
August 12, 2014 3:42 pm

I always try to research these stories myself, instead of jumping on board a newsletter. It may be that Michael has access to some infromation not availabe to us through our own research, but one thing is certain. We can track the stock by it’s symbol, or just access the companie’s website. The stock sure ain’t gonna skyrocket overnight. I say, when it is listed on the NASDAQ, you can certainly get it’s listing at the company’s website and follow it like you would any other stock. I know I will.

Add a Topic
5971
Add a Topic
5971
Add a Topic
5971
Bakermre
Irregular
Bakermre
August 12, 2014 3:51 pm

The usual suspects, Stansberry, Agora and Oxford seem to be behind this one as well! How many slick con jobs do we have to endure, listening to this sort of super hype for more than an hour, before we realize these guys are false prophets? Did you notice that Mr. Robinson claimed to have discovered and promoted Rare Earth miners and companies, forecast to rocket up to stellar profits, some years ago? Follow up on that one and you’ll discover rare fallen meteors like Great Western, Quest, etc. Woe be to investors in those speculations, (also listed on the TSX-Venture Exchange). How these people go on and on, year after year, with their storms of breathless e-mail salvos, and side step real legal pitfalls, amazes me! Well, Porter Stansberry had a near miss with his SEC battle, refund of subscribers deposits, legal defense fees and related expenses, including a big SEC fine on one of these sojourns some years ago. Luckily, he only had a civil complaint and avoided jail time. Cost him $1 million +, so he claims. My advice: with friends like these no enemies needed.

Add a Topic
6137
Add a Topic
150
Add a Topic
388
ALB
Member
ALB
August 13, 2014 3:56 pm
Reply to  Bakermre

That’s a brilliant analysis! I’ve subscribed to many of these “analysts” and I rarely make money from their suggestions; I usually end up losing. We gravitate to these newsletter writers because we don’t trust our own financial judgement.

thi is frank,
August 13, 2014 7:57 pm
Reply to  Bakermre

I agree with you, and I read something in a different newsletter about these mines which they exist and they produce graphite, the one in Ontario is about 200 miles from where I live and has potential, being 20 miles from railway track/route for shipping to supply Panasonic for lithium batteries, the other one is in quebec which has high quality graphite, but I believe it will be very hard to ship and the cost would be high, guys ceck them for yourself.

Add a Topic
2575
Add a Topic
2096
Add a Topic
2575
DB
Member
DB
August 12, 2014 4:03 pm

What this and several other the companies in the revolutionary Alzheimers treatment space need is a concomitantly administered drug that transiently opens the blood brain barrier and allows all treatments to pass through it. Otherwise the treatment can’t get to where it can help.

vivian lewis
August 12, 2014 4:07 pm

Hi there. the numbers do not compute. A gram is about 1/30th of an ounce. There are 30 grams in an ounce. There are 1000 grams in a kilogram which is equal to about 2.2 pounds. I think the idea is that the arithmetic is supposed to be easy. But you need to add another factor: a milligram which is 1/1000th of a gram. Luckily (or not) I had to learn this when living in France for ages to shop and even to cook.
Meanwhile a thimble-ful is a measure of volume. The metric system measures volume with liters. A liter is about a US quart. And a liter of water weighs a kilogram. This magically will enable you to work out the price per thimbleful of this stuff if you know how many thimbles in a liter, or if this metallic substance is like water (unlikely) in how much it weighs. The use of all this foreign stuff is essentially flim-flam in my opinion, just like not telling us these are keyhole limpets.

Add a Topic
540
Add a Topic
540
Alan Harris
Guest
Alan Harris
August 16, 2014 4:35 pm
Reply to  vivian lewis

Surely its easy….if a thimble full = $1300 of gold, $1400 of platinum… how much weight of gold/plat is $1300-$1400. Now you know how much a thimble holds.

Add a Topic
210
Add a Topic
1292
KennyG
KennyG
August 12, 2014 4:14 pm

Whatever is pumping SBOTF seems to be working as it is up 30% today. As Travis stated, Stellar has been pumped by several newsletters for at least a year that I am aware of and it was always the same story. It would receive an immediate boost and always came back down. Caution is the word.

👍 3533
Dave
Dave
August 12, 2014 4:19 pm

“the KLH product is in a vial of 0.75ml for 20 grams”

Hi Travis, decimal issues. Assuming you mean that the 0.75ml contents weigh 20 grams, this cannot be correct. Maybe 20mg of the active ingredient in 0.75 ml of water?

Re 20 grams, Even depleted uranium (very dense stuff used for bunker/tank-buster munitions) isn’t that dense. Water weighs 1g per ml and even if the vial is pure protein rather than protein dissolved in water, it’s not going to weigh much more than 0.75 gram, or 750 mg.
Then there’s the thimble problem: there’s more than one type of thimble (e.g., http://en.wikipedia.org/wiki/Alcoholic_spirits_measure) and the latter type vary in a very big way, volume-wise, from 25ml to 250ml.

Whatever—-the limpet product is doubtless very expensive.

Add a Topic
540
Add a Topic
520
Add a Topic
540
Bakermre
Irregular
Bakermre
August 12, 2014 4:26 pm

Travis, I just love Stock Gumshoe! Many, many thanks to you and this service. You are the Snopes.com for investors. A bright light that shines into the darkness of contemporary investment letter promoters, charletons, P.T. Barnum clones and slight of hand, slip of lip double talkers who seek to “advise” us for a big fat fee. “Liquid Metal” for us chemists is Mercury, (Hg) a deadly poison. An appropriate synoname for Mr. Robinson’s (worthless) yet very costly advice.

Add a Topic
5971
dunnydame
dunnydame
August 13, 2014 3:33 pm
Reply to  Bakermre

Hi Baker – I too immediately thought of mercury – and certainly not limpets. And I second your description of SG as the Snopes.com for investors.
Penny

👍 1211
modernrock
Irregular
August 12, 2014 4:35 pm

in at .95 average from yesterdays sleuthing and posting in discussions forum. Added on the open, flipped today’s @ 1.32 at close and 1/3 from yesterday at 1.32. You don’t marry these things people!!

👍 255
modernrock
Irregular
August 13, 2014 4:51 pm
Reply to  modernrock

another 1/3 out the door at 1.39 near close, the second dip today would have been buyable after more emails were sent with different descriptors

👍 255
Bakermre
Irregular
Bakermre
August 12, 2014 4:42 pm

I am a Canadian, living in Canada. When we get USA based dividends, the US IRS automatically deducts 15% from the total; so we get 85% net sent to us here. Evidently, there is a reciprocal 15% with-held by Revenue Canada, when a Canadian based company sends funds back to a “USA person”, presumably a US citizen, living in the USA. Mr. Robinson is again engaging in very convoluted double-talk about US/Canada tax policies and or tax treaties as applied in this proposition. VERY, DUBIOUS ADVICE! He should be a licensed accountant or “Chartered Canadian Accountant” to engage in such rhetoric!

Add a Topic
1515
Add a Topic
152
Add a Topic
1340
KennyG
KennyG
August 12, 2014 5:06 pm
Reply to  Bakermre

But doesn’t that reciprocal agreement between the two countries apply only to dividends? Not capital gains as implied in the Robinson tease.

Add a Topic
152
👍 3533
Alan Harris
Guest
Alan Harris
August 16, 2014 4:44 pm
Reply to  KennyG

I dont think so Kenny. I get US taxed on any profit, then claim it back in UK….then pay UK tax on that profit at UK rates. So as always with tax, they give with one hand and take away with the other. Yes you get $4k refund, plus a 4k bill from your own tax man! I thnk he’s being ‘economic with the truth’.

Add a Topic
372
IanS
IanS
August 12, 2014 5:01 pm

A Limpet, lest anyone forgets, is very difficult to shift. Once you have one attached to your boat or pier you are stuck with it. This adhesion is achieved with a Big Sucker. Investors cannot complain – in the case of this particular pump and dump – that there were no clues as to their fate in the blurb.

IanS
IanS
August 12, 2014 5:17 pm

A bizarre and almost total misread by all commentators. The Blurb which Travis quotes in his reply above says LIVING Metal not LIQUID Metal. These are two different things and oddly enough though KLH is the right company for this LIVING Metal teaser, there was a LIQUID Metal teaser around in January leading to a company LQMT Liquidmetal Technologies Inc which tripled in price very briefly in January.

Add a Topic
1340
👍 21717
KennyG
KennyG
August 12, 2014 5:18 pm

Just today alone, I have received 4 emails from 4 different newsletters with the Robinson tease. That would explain todays price action with Stellar Bio being up 30%.

👍 3533

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
34
0
Would love your thoughts, please comment.x
()
x